| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2004-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bafdd0c3f53912ae3e4308d3b58ab81c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6720307c62ffe19d207d2db62f55ab0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abe65b624000df6c3cfb7efebc6a156b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_038d63f551be61efda863b13bd8a3feb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56a0aff8c8d72cdd5c627ebe8e72a94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc74fbad1004537e4f75e92b514a24de |
| publicationDate |
2006-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1615653-A2 |
| titleOfInvention |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| abstract |
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. |
| priorityDate |
2003-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |